Pharmacist-Led Study in Controlling Hypoglycemia in Older Adults With Type 2 Diabetes Mellitus

Diabetes Mellitus Type 2 With Hypoglycemia Clinical Trial

— ROSE-ADAM  

Official title:

Randomized Controlled Trial of Pharmacist-Led Patient Counselling in Controlling Hypoglycemic Attacks in Older Adults With Type 2 Diabetes Mellitus

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04081766
• Other study ID #: 2019-May-0170
• Status: Completed
• Phase: N/A
• Start date: February 9, 2020
• Est. completion date: December 31, 2020

Study information

• Verified date: November 2020
• Source: University of Lincoln
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study involves two parts: a randomised controlled trial, and a nested qualitative study.

The main aim of the trial is to evaluate the effectiveness of a pharmacist-led, medications-focused patient counselling on reducing the frequency of hypoglycaemia in older adults diagnosed with type 2 Diabetes Mellitus within 12 weeks in Jordan.

The study hypothesis is that individualised patient counselling which is provided by pharmacists and involves recommendations about anti-diabetic medications will reduce the risk of hypoglycaemia by preventing further episodes in the elderly Jordanians with type 2 Diabetes Mellitus.

The qualitative study aims at evaluating the experience of participants in both groups with the study (process evaluation). This involves exploring which components are effective and which are not with the reasons, the contextual factors affecting the delivery and implementation of the study and the intervention, and how the study and the intervention can be scaled up in the future.

Description:

Hypoglycaemia is the most serious adverse effect of diabetes treatment. Older adults are at the highest risk to develop hypoglycaemia. Several studies have established the important positive role of educational interventions on achieving glycaemic control and other clinical outcomes, however, there is still a lack in clinical trials that evaluate the impact of such type of interventions on hypoglycaemia risk, especially in older adults. Despite the increasing prevalence of chronic diseases such as diabetes in Jordan, pharmacists still provide traditional services rather than patient-centred services.

The purpose of this research is to investigate the effect of pharmacist-led, individualised, and medications-focused patient counselling on reducing episodes of hypoglycaemia compared to the usual care in older Jordanians with type 2 Diabetes Mellitus within 12 weeks.

This research is a prospective, open-label, randomised controlled trial that is conducted in the outpatient endocrinology and cardiology clinics at King Abdullah University Hospital in Jordan, with 204 elderly patients who had been diagnosed with type 2 diabetes. Participants will be randomised in a 1:1 ratio into either the intervention (SUGAR Handshake) or the usual care groups. Each participant in the SUGAR Handshake group will receive a face-to-face individualised educational session with a pharmacist at the inclusion visit, a pictogram containing the main educational information, and a reinforcement of the educational session through a phone call at week 6 of the inclusion visit. They will also receive the usual care provided by the health care professionals at the outpatient clinics. On the other hand, patients in the usual care group will only receive the routine care provided at the outpatient clinics. The duration of the trial for each participant is 12 weeks.

The qualitative study is performed through phone interviews with 8-12 participants of each group at week 6 of the inclusion visit. Participants are to be approached according to convenience sampling and the data will be analysed using content analysis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 212
• Est. completion date: December 31, 2020
• Est. primary completion date: December 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• Confirmed diagnosis of type 2 Diabetes Mellitus

• Have been taking a sulfonylurea, insulin, or any three or more anti-diabetic medications

Exclusion Criteria:

• Unable to understand instructions or to give consent.

• Impaired mental capacity

• On palliative care for cancer, with advanced-stage or end-stage diseases, who have psychosis or severe depression, who are terminally-ill, or with life expectancy < 6 months

• Have been diagnosed with haemolytic anaemia or hemoglobinopathies as being self-reported or according to the patient's electronic record.

• Unwilling to take home glucose measurements or to use the glucometer (for example because of severe hearing or visual impairment and without a caregiver to measure the blood glucose level by the glucometer)

• Unwilling to return for follow up.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus Type 2 With Hypoglycemia
• Diabetes Mellitus, Type 2
• Hypoglycemia

Intervention

Behavioral:
• SUGAR Handshake
An interactive patient counselling session delivered by a pharmacist which mainly focuses on medication-related instructions towards preventing hypoglycaemia in addition to recommendations about hypoglycemia early recognition, causes, and treatment. The SUGAR Handshake is individualised according to shared decision making and each participant's characteristics. Components of the SUGAR Handshake intervention will be covered under five main domains: Signs and symptoms of hypoglycemia. Understanding the underlying causes of hypoglycaemia such as misuse of anti-diabetic medications. Good glycaemic control and self-monitoring, which mainly includes instructions on handling the anti-diabetic medications. Acknowledgement by the patient Recap and summary The pictogram contains the main recommendations for easy recall by the participant. Moreover, the intervention will be reinforced by a phone call at week 6 of the inclusion visit.

Locations

Country	Name	City	State
Jordan	King Abdullah University Hospital	Irbid

Sponsors (1)

Lead Sponsor	Collaborator
University of Lincoln

Country where clinical trial is conducted

Jordan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Frequency of total episodes of hypoglycaemia	The frequency of hypoglycemia will be calculated as the number of total hypoglycemic episodes/person/ 12 weeks. Total hypoglycemia is defined as the summation of severe, symptomatic, and asymptomatic episodes of hypoglycaemia.	12 weeks
Secondary	Frequency of severe hypoglycaemia	The frequency of severe hypoglycemia will be calculated as the number of severe hypoglycemic episodes/person/ 12 weeks. Severe hypoglycemia is defined as any event requiring the assistance of another person to administer carbohydrate and glucagon or take any other corrective actions, accompanied by neurological recovery after the corrective actions.; Participants will be provided with diaries to document severe episodes of hypoglycemia	12 weeks
Secondary	Frequency of asymptomatic hypoglycemia	The frequency of asymptomatic hypoglycemia will be calculated as the number of asymptomatic hypoglycaemia episodes/person/ 12 weeks. asymptomatic hypoglycaemia is defined as an event not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose concentration =70 mg/dL (=3.9 mmol/L).; Participants will be provided with diaries to document fasting blood glucose levels by which asymptomatic episodes will be diagnosed.	12 weeks
Secondary	Frequency of symptomatic hypoglycemia	The frequency of symptomatic hypoglycemia will be calculated as the number of symptomatic hypoglycemic episodes/person/ 12 weeks. Symptomatic hypoglycemia is defined as an event during which the patient experiences typical symptoms of hypoglycaemia (sweating, dizziness, light-headedness, tremor, hunger, headache) whether they are accompanied by a measured plasma glucose concentration =70 mg/dL (=3.9 mmol/L) or not.; Participants will be provided with diaries to document symptomatic episodes of hypoglycemia.	12 weeks
Secondary	Proportion of patients experiencing hypoglycaemia	proportion of patients who experience at least one hypoglycaemic attack of each type	12 weeks
Secondary	Time to the first hypoglycaemic attack	the number of the day when a participant will experience the first hypoglycaemic attack of any type after randomisation.	12 weeks